NCT06334497View on ClinicalTrials.gov

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

November 30, 2027

Conditions
Cytomegalovirus Infection
Interventions
DRUG

Letermovir

"480mg (2X240mg- tablets) of Letermovir given orally once a day until the treatment success or the treatment failure, up to 12 weeks. In case of co-administration with cyclosporine A, the dosage of Letermovir will be reduced."

DRUG

Valganciclovir

"Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced."

DRUG

Letermovir placebo

"480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks"

Trial Locations (1)

75015

RECRUITING

Hôpital Necker Enfants Malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER